A recognition molecule can be used as one component of a larger therapeutic design. Its ability to bind is one property of that component.
Primary antibody-fragment studies showed how recognition domains can be used outside a complete antibody. Experiments with bispecific T-cell engagers then showed that constructs with similar binding affinity could differ in target-cell lysis because of epitope position and antigen geometry. A binder is therefore a module whose performance must be evaluated in its assembled format. Binding alone does not establish delivery, effector activity or clinical benefit. In a 1993 experiment a single-chain Fv joined to a T-cell receptor signalling chain was expressed in a cytolytic T-cell hybridoma and triggered interleukin-2 secretion and hapten-specific, non-MHC-restricted target-cell lysis (Eshhar et al.), an early demonstration of recognition coupled to activation in one cell model. In a 2022 mouse heart-failure model, lipid nanoparticles carrying CAR mRNA and targeted to CD5 delivered the message to T cells and reduced fibrosis, an example of a binder choosing the cell that receives instructions rather than the cancer cell (Rurik et al.). FDA's March 2024 antibody-drug conjugate clinical pharmacology guidance treats the conjugate and its constituent parts separately.
Shares Binder affinity, epitope and developability, Immune measurements and product evidence.
Shares Delivery targets and therapeutic targets, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/